

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

FEB 1 2 2002

Atty. Docket No.

ARCD:347US/MBW

Serial No.

09/974,749

Applicant

Chun-Su Yuan

Filing Date:

October 9, 2001

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>g</i>	C1	Abraira <i>et al.</i> , "Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial," <i>Diabetes Care</i> :18(8):1113-1123, 1995.
<i>g</i>	C2	Attele <i>et al.</i> , "Ginseng pharmacology. Multiple constituents and multiple actions," <i>Biochem. Pharmacol.</i> , 58:1685-1693, 1999.
<i>g</i>	C3	Bailey, "Insulin resistance and antidiabetic drugs," <i>Biochem Pharmacol</i> , 58: 1511-1520, 1999.
<i>g</i>	C4	Bensky and Gamble, <i>Chinese Herbal Medicine. Materia Medica</i> , 1993.
<i>g</i>	C5	Bonadonna <i>et al.</i> , "Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes," <i>J Clin Invest</i> , 92(1):486-494, 1993.
<i>g</i>	C6	Brownlee <i>et al.</i> , "Nonenzymatic glycosylation and the pathogenesis of diabetic complications," <i>Ann Intern Med</i> , 101:527-537, 1984
<i>g</i>	C7	Davydov <i>et al.</i> , "Efficacy of ginseng drugs in experimental insulin-dependent diabetes and toxic hepatitis," <i>Patologicheskaya Fiziologiya i Eksperimentalnaya Terapiya</i> 5: 49-52, 1990. Article in Russian; Abstract included.
<i>g</i>	C8	DeFronzo <i>et al.</i> , "Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (Type II) diabetes mellitus," <i>J Clin Invest.</i> , 76:149-155, 1985.
<i>g</i>	C9	Eriksson <i>et al.</i> , "Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus," <i>New Eng J Med</i> , 321(6):337-343, 1989.

25094487.1

EXAMINER:

K-C. Soren

DATE CONSIDERED:

03/31/2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Paper # 4

RECEIVED
FEB 1 5 2002
MAR 1 9 2002TECH CENTER 1600/2900
TECH CENTER 1600/2900

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Atty. Docket No.

ARCD:347US/MBW

Serial No.

09/974,749

Applicant

Chun-Su Yuan

Filing Date:

October 9, 2001

Group:

1614

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>J</i>	C10	Ferrannini <i>et al.</i> , "Hepatic glucose production in Insulin-resistant states," <i>Diabetes Metab Rev</i> , 5(8): 711-725, 1989.
<i>J</i>	C11	Ferrannini, "Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects," <i>Endocrine Rev.</i> , 19:477-490, 1998.
<i>J</i>	C12	Firth <i>et al.</i> , "Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus," <i>J Clin Invest</i> , 77:1525-1532, 1986.
<i>J</i>	C13	Garvey <i>et al.</i> , "Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity," <i>J Clin Invest</i> , 87:1072-1081, 1991.
<i>J</i>	C14	Gaster and Hirsch, "Sliding scale insulin use and rates of hyperglycemia," <i>Arch Intern Med</i> , 158(1):134-140, 1998.
<i>J</i>	C15	Gillis, "Panax ginseng pharmacology: a nitric oxide link," <i>Biochem Pharmacol</i> , 54:1-8, 1997.
<i>J</i>	C16	Ginsberg <i>et al.</i> , "Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia," <i>J Clin Invest</i> , 55: 454-461, 1975.
<i>J</i>	C17	Guma <i>et al.</i> , "Insulin induces translocation of GLUT-4 glucose transporters in human skeletal muscle," <i>Am J Physiol</i> , 268: E613-E622, 1995.
<i>J</i>	C18	Horikawa <i>et al.</i> , "Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus," <i>Nature Genetics</i> 26(2):163-175, 2000.
<i>J</i>	C19	Huang, <i>The Pharmacology of Chinese Herbs</i> , CRC Press, Boca Raton, FL, 1999.
<i>J</i>	C20	Ihara, "Hyperglycemia causes oxidative stress in pancreatic β -cells of GK rats, a model of type 2 diabetes," <i>Diabetes</i> , 48:927-932, 1999.
<i>J</i>	C21	Kashiwagi <i>et al.</i> , "In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus," <i>J Clin Invest</i> , 72:1246-1254, 1983.
<i>J</i>	C22	Kelley <i>et al.</i> , "Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes," <i>J Clin Endocrinol Metab</i> , 77(5):1287-1293, 1993.
<i>J</i>	C23	Kimura and Suzuki. "The pattern of action of blended Chinese traditional medicines to glucose tolerance curves in genetically diabetic KK-CA ^y mice," <i>J Pharm Dyn</i> , 4:907-915, 1981.

25094487.1

EXAMINER:

K.C. Smith

DATE CONSIDERED:

03/31/2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
FEB 15 2002
TECH CENTER 1600/2900

MAR 19 2002

RECEIVED

Form PTO-1449 (modified)

List of Patents and Publications for Applicants

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1Atty. Docket No.
ARCD:347US/MBWSerial No.
09/974,749Applicant
Chun-Su YuanFiling Date:
October 9, 2001Group:
1614

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>g</i>	C24	Kimura <i>et al.</i> , "Effects of hypoglycemic components in ginseng radix on blood insulin level in alloxan diabetic mice and on insulin release from perfused rat pancreas," <i>J Pharm Dyn</i> , 4:410-417, 1981.
<i>g</i>	C25	Kimura <i>et al.</i> , "Pharmacological sequential trials for the fractionation of components with hypoglycemic activity in alloxan diabetic mice from ginseng radix," <i>J Pharm Dyn</i> , 4:402-409, 1981.
<i>g</i>	C26	Kimura <i>et al.</i> , "The antihyperglycaemic blend effect of traditional Chinese medicine Byakko-ka-ninjin-to on Alloxan and diabetic KK-CA ^y mice," <i>Phytotherapy Research</i> , 13:484-488, 1999.
<i>g</i>	C27	Kimura, "Hypoglycemic component in ginseng radix and its insulin release," Proceedings of the 3rd International Ginseng Symposium. Korean Ginseng Research Institute, Seoul, Korea, 1980.
<i>g</i>	C28	Klein and Klein, "Relation of glycemic control of diabetic complications and health outcomes," <i>Diabetes Care</i> , 21 (Suppl. 3): C39-C43, 1998.
<i>g</i>	C29	Klein <i>et al.</i> , "Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy," <i>Arch Intern Med</i> , 154: 2169-2178, 1994.
<i>g</i>	C30	Kruszynska and Olefsky, "Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus," <i>J Invest Med</i> , 44: 413-428, 1996.
<i>g</i>	C31	Lee, <i>Facts about Ginseng, the Elixir of Life</i> , Hollyn International Corp., Elizabeth, NJ, 1992.
<i>g</i>	C32	Lillioja <i>et al.</i> , "Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus," <i>N Eng J Med</i> , 329:1988-1992, 1993.
<i>g</i>	C33	Liu <i>et al.</i> , "Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses," <i>Diabetologia</i> , 36:428-432, 1993.
<i>g</i>	C34	Mitrakou <i>et al.</i> , "Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM," <i>Diabetes</i> , 39: 1381-1390, 1990.
<i>Not</i>	C35	Molokovskii and Barnaulov, "Protective properties of Panax ginseng leaf tincture in immobilization stress and alloxan diabetes ," <i>Rastitel'nye Resursy</i> , 22: 387-393, 1986. Article in Russian.

25094487.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED

MAR 19 2002

TECH CENTER 1600/2900

RECEIVED

Form PTO-1449 (modified)		Atty. Docket No. ARCD:347US/MBW	Serial No. 09/974,749
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Chun-Su Yuan	
		Filing Date: October 9, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C36	Molokovskii <i>et al.</i> , "The action of adaptogenic plant preparations in experimental alloxan diabetes," <i>Problemy endokrinologii</i> , 35: 82-87, 1989. Article in Russian, Abstract included.
	C37	Ohkubo <i>et al.</i> , "Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study," <i>Diabetes Res Clin Pract</i> , 28:103-117, 1995.
	C38	Okuda and Yoshida, "Studies on the effects of ginseng components on diabetes mellitus," Proceedings of the 3rd International Ginseng Symposium, Korean Ginseng Research Institute, Seoul, Korea, 1980, 53-57.
	C39	Reaven, "Insulin resistance in noninsulin-dependent diabetes mellitus," <i>Am J Med</i> , 74: 3-17, 1983.
	C40	Sakurai and Tsuchiya, "Superoxide production from nonenzymatically glycosylated protein," <i>FEBS Lett</i> , 236(2):406-410, 1988.
	C41	Seely and Olefsky, "Potential cellular and genetic mechanisms for insulin resistance in the common disorders of diabetes and obesity," Chapter 7: In: Moller D, ed. <i>Insulin resistance and its clinical disorders</i> . Chichester: John Wiley & Sons, Ltd, 1993: 187-252.
	C42	Shen <i>et al.</i> , "Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes," <i>J Clin Invest</i> , 49:2151-2160, 1970.
	C43	Shepherd <i>et al.</i> , "Cellular defects in glucose transport: lessons from animal models and implications for human insulin resistance," Chapter 8 In: Moller DE, ed. <i>Insulin resistance</i> . Chichester: John Wiley and Sons Ltd. 1993; 253-300.
	C44	Sotaneimi <i>et al.</i> , "Ginseng therapy in non-insulin-dependent diabetic patients," <i>Diabetes Care</i> , 18(10):1373-1375, 1995.
	C45	Stolk <i>et al.</i> , "Retinopathy, glucose, and insulin in an elderly population: the rotterdam study," <i>Diabetes</i> , 44(1):11-15, 1995.
	C46	Taylor <i>et al.</i> , "Perspectives in Diabetes. Insulin resistance or insulin deficiency which is the primary cause of NIDDM?" <i>Diabetes</i> , 43:735-740, 1994.
	C47	Vuksan <i>et al.</i> , "American ginseng (<i>Panax quinquefolius</i> L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus," <i>Arch Int Med</i> , 160:1009-1013, 2000.

25094487.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
MAR 1 9 2002

RECEIVED

FEB 1 5 2002
TECH CENTER 1600/2900

TECH CENTER 1600/2900

RECEIVED
RECEIVED

FEB 15 2002

MAR 19 2002

Page 5 of 5

TECH CENTER 1600/2900
TECH CENTER 1600/2900

Form PTO-1449 (modified)

FEB 12 2002

Atty. Docket No.

ARCD:347US/MBW

Serial No.

09/974,749

List of Patents and Publications for Applicant's

Applicant

Chun-Su Yuan

INFORMATION DISCLOSURE STATEMENT

Filing Date:

October 9, 2001

Group:

1614

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C48	Warram <i>et al.</i> , "Slow glucose removal rate and hyperinsulinemia prececed the development of type II diabetes in the offspring of diabetic parents," <i>Ann Inten Med</i> , 113:909-915, 1990.
	C49	Yki-Jarvinen, "Glucose toxicity," <i>Endocrine Rev</i> 13(3): 415-431, 1992.
	C50	Yokozawa and Oura, "Increased hepatic adenine nucleotide content by ginseng," <i>J Ethnopharmacol</i> , 34: 79-82, 1991.
	C51	Yokozawa <i>et al.</i> , "Effects of ginsenoside-Rb ₂ on adenine necleotide content of rat hepatic tissue," <i>J Pharm Pharmacol</i> , 43:290-291, 1991.
	C52	Yokozawa <i>et al.</i> , "Molecular biological analysis of the effects of ginsenoside-Rb ₂ on albumin mRNA in Streptozotocin-induced diabetic rats," <i>J Pharm Pharmacol</i> , 48:763-767, 1996.
	C53	Yokozawa <i>et al.</i> , "Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb ₂ in streptozotocin-diabetic rats," <i>Chem Pharm Bull</i> , 33(2)869-872, 1985.
	C54	Yuan <i>et al.</i> , "Gut and brain effects of American ginseng root on brainstem neuronal activities in rats," <i>American Journal of Chinese Medicine</i> , 26(1):47-55, 1998.
	C55	Yuan <i>et al.</i> , "Modulation of American ginseng on brainstem GABAergic effects in rats," <i>Journal of Ethnopharmacology</i> , 62:215-222, 1998.
	C56	Yuan <i>et al.</i> , "Panax Quinquefolium L. inhibits thrombin-induced endothelin release in vitro," <i>American Journal of Chinese Medicine</i> , 27(3-4):331-338, 1999.

25094487.1

EXAMINER:

DATE CONSIDERED:

04/01/2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)